Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/27 10:00:19 pm
58.6 USD   +0.41%
08:47a MERCK : and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker ..
07/27DJBayer Reports Higher Second-Quarter Profit, Raises Guidance
07/26 MERCK : Announces Fourth-Quarter 2016 Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CEST
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
08:47a MERCK : and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to C..
07/27DJBayer Reports Higher Second-Quarter Profit, Raises Guidance
07/26 MERCK : Announces Fourth-Quarter 2016 Dividend
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
07/25 MERCK : Receives Breakthrough Therapy Designation from FDA and PRIME Status from..
07/22 MERCK : Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (r..
07/21 MERCK ANIMAL HEALTH : Receives FDA Approval of BRAVECTO® (fluralaner topical sol..
07/21 MERCK : Provides Regulatory Update on Biologics Licensing Application for Invest..
07/21 MERCK : Patent Issued for Preparation of Crystalline Forms of Dihydropyrazolopyr..
07/21 MERCK : Findings in Pseudohypoparathyroidism and Genetics Reported from Merck & ..
More news
Sector news : Pharmaceuticals - NEC
10:16aDJASTRAZENECA : Posts $3 Million Loss
10:03aDJASTRAZENECA : Posts $3 Million Loss -- Update
09:58a Weak China sales drag down Smith & Nephew profits
08:49aDJBREXIT SURPRISE : A Loss and Gain For U.K.'s Glaxo -- WSJ
08:49aDJEarnings Watch -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/27 Residential REITs Replace Diversified Dogs Atop Real Estate Sector Household ..
07/27 Gilead Sciences' Sales Forecast Confirms Concerns
07/27 Are Consumers Buying SUVs And Trucks? Ford Results Might Give Insight
07/27 JULY BASIC MATERIALS : Coal Tops By Yield But Cellulose, Carbon, Copper, And Che..
07/26 Merck declares $0.46 dividend
Advertisement
Financials ($)
Sales 2016 39 492 M
EBIT 2016 13 526 M
Net income 2016 6 428 M
Debt 2016 3 946 M
Yield 2016 3,15%
P/E ratio 2016 25,66
P/E ratio 2017 19,68
EV / Sales 2016 4,21x
EV / Sales 2017 4,20x
Capitalization 162 206 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 61,9 $
Spread / Average Target 5,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.10.94%162 206
JOHNSON & JOHNSON21.47%343 198
PFIZER INC.14.16%223 490
ROCHE HOLDING LTD.-9.99%216 972
NOVARTIS AG-5.30%216 918
BRISTOL-MYERS SQUIBB C..11.16%127 652
More Results